Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Benzinga12-14

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491302522?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uI4OafKdqumkkqx_HY1gvw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/83e707c5ba3952b58fca54fa366205fe","is_english":true,"pubTime":"2024-12-14 03:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491302522","market":"us","top_or_hot":-1,"title":"Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?","media":"Benzinga","content":"<div>\n<p>Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-amicus-immunocore-immuneering-stocks-191050213.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 03:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-amicus-immunocore-immuneering-stocks-191050213.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-amicus-immunocore-immuneering-stocks-191050213.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0098860793.USD","symbol_name":"FRANKLIN INCOME \"A\" INC","start_time":0,"source_url":"https://finance.yahoo.com/news/why-amicus-immunocore-immuneering-stocks-191050213.html","article_id":"2491302522","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uI4OafKdqumkkqx_HY1gvw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/83e707c5ba3952b58fca54fa366205fe"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491302522","pubTimestamp":1734117050,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Morgan Stanley downgraded Amicus Therapeutics Inc . Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares.The analyst downgraded the stock to Equal-weight from Overweight and lowered the price target from $17 to $12.Investors have shifted focus to what will provide the company’s next leg of growth. The analyst would look to see potential updates to the company’s pipeline in 2025 and beyond, as those programs have the greatest potential to unlock further value for Amicus stock.Morgan Stanley has also lowered the price target for Immunocore Holdings plc  from $74 to $35 on launch timing and pricing for brenetafusp given disappointing data earlier this year in cutaneous melanoma","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4139":"生物科技","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IMCR":"Immunocore Holdings plc","TSYW.SI":"TESLA 3xLongSG261006","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","SQQQ":"纳指三倍做空ETF","BK4534":"瑞士信贷持仓","BK4588":"碎股","TQQQ":"纳指三倍做多ETF","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1",".IXIC":"NASDAQ Composite","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","FOLD":"爱美医疗","IMRX":"Immuneering Corp","USJW.SI":"ALPHAB 3xLongSG261006","PSQ":"纳指反向ETF","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4505":"高瓴资本持仓","BK4581":"高盛持仓","QLD":"纳指两倍做多ETF","BK4504":"桥水持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0971096721.USD":"富达环球金融服务 A","BK4563":"昨日强势股","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4127":"投资银行业与经纪业","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0106831901.USD":"贝莱德世界金融基金A2","BK4539":"次新股","NVIW.SI":"NVDA 3xLongSG261006","QID":"纳指两倍做空ETF","USAW.SI":"AMZN 3xLongSG261006","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H"},"translate_title":"为什么Amicus、Immunocore和Immuneering股票周五交易走低？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRX":1,"FOLD":1,"IMCR":1,".IXIC":0.69,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.\nThe analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares.\nThe analyst downgraded the stock to Equal-weight from Overweight and lowered the price target from $17 to $12.\nInvestors have shifted focus to what will provide the company’s next leg of growth. The analyst would look to see potential updates to the company’s pipeline in 2025 and beyond, as those programs have the greatest potential to unlock further value for Amicus stock.\nMorgan Stanley has also lowered the price target for Immunocore Holdings plc (NASDAQ:IMCR) from $74 to $35 on launch timing and pricing for brenetafusp given disappointing data earlier this year in cutaneous melanoma and ovarian cancer.\nThe analyst continues to give full credit for Kimmtrak (tebentafusp), which was approved for unresectable or metastatic uveal melanoma.\nMorgan Stanley sees limited upside potential from additional brenetafusp updates as the company continues to detect signals in metastatic NSCLC and combination in earlier-line NSCLC.\nThe analyst downgraded the stock from Overweight to Equal-Weight rating.\nMorgan Stanley downgraded Immuneering Corp (NASDAQ:IMRX) shares to Underweight from Equal-weight and set a base case range of $1 to $5 versus its previous target of $4. While supporting Immuneering’s strategy of targeting the MAPK pathway with deep cyclic inhibition, the analyst notes other stronger investment opportunities in the coverage on a relative basis.\nEarly clinical results have been promising, but analysts emphasize the need for more robust data with a larger patient pool to confirm that these outcomes aren’t coincidental or limited to specific cases. Additionally, the analyst expressed greater caution regarding the potential of IMM-1-104 in indications outside of pancreatic cancer.\nPrice Action: IMRX stock is down 18% at $1.615, IMCR stock is down 5.89% at $28.53, and FOLD stock is down 6.70% at $9.47 at last check Friday.\nRead Next:\n\nNetflix Adjusts Parental Leave Policy, But There Is A Catch\n\nPhoto via Shutterstock.\nLatest Ratings for IMRX\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nJan 2022\nPiper Sandler\nInitiates Coverage On\n\nOverweight\n\n\nAug 2021\nCowen & Co.\nInitiates Coverage On\n\nOutperform\n\n\nAug 2021\nGuggenheim\nInitiates Coverage On\n\nBuy\n\n\n\n View More Analyst Ratings for IMRX \n View the Latest Analyst Ratings \nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nAMICUS THERAPEUTICS (FOLD): Free Stock Analysis Report\n\nThis article Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491302522"}